Morten Thorsteinsson1, György Söletormos, Per Jess. 1. Department of Surgery, Roskilde Hospital, University of Copenhagen, Koegevej 7-13, DK-4000 Roskilde, Denmark. moth@regionsjaelland.dk
Abstract
BACKGROUND: The aim of the present study was to detect circulating tumor cells (CTCs) in the peripheral blood of patients with non-metastatic colon cancer and to evaluate whether there is a diurnal variation in the CTC counts. Furthermore, the study aimed to examine the correlation between CTCs and TNM stage, other paraclinical variables and prognosis. PATIENTS AND METHODS: Blood samples were collected from 20 consecutive patients with colon cancer TNM stage I-III at four different perioperative time points. Detection of CTCs was performed using the immunological assay CellSearch®. RESULTS: CTCs were detected in 1 out of 60 preoperative blood samples, resulting in a detection rate of 1 in 20 patients (5%; 95% confidence interval = 0.1-25%). None of the postoperative blood samples had CTC levels above the cut-off value (≥ 2 CTCs/7.5 ml blood). CONCLUSION: The presence of CTCs in non-metastatic colon cancer is rare and barely detectable with the only commercially available assay for detection of CTCs, the CellSearch System.
BACKGROUND: The aim of the present study was to detect circulating tumor cells (CTCs) in the peripheral blood of patients with non-metastatic colon cancer and to evaluate whether there is a diurnal variation in the CTC counts. Furthermore, the study aimed to examine the correlation between CTCs and TNM stage, other paraclinical variables and prognosis. PATIENTS AND METHODS: Blood samples were collected from 20 consecutive patients with colon cancerTNM stage I-III at four different perioperative time points. Detection of CTCs was performed using the immunological assay CellSearch®. RESULTS: CTCs were detected in 1 out of 60 preoperative blood samples, resulting in a detection rate of 1 in 20 patients (5%; 95% confidence interval = 0.1-25%). None of the postoperative blood samples had CTC levels above the cut-off value (≥ 2 CTCs/7.5 ml blood). CONCLUSION: The presence of CTCs in non-metastatic colon cancer is rare and barely detectable with the only commercially available assay for detection of CTCs, the CellSearch System.
Authors: Paola Gazzaniga; Walter Gianni; Cristina Raimondi; Angela Gradilone; Giuseppe Lo Russo; Flavia Longo; Orietta Gandini; Silverio Tomao; Luigi Frati Journal: Tumour Biol Date: 2013-03-29
Authors: Elena Magni; Edoardo Botteri; Paola S Ravenda; Maria C Cassatella; Emilio Bertani; Antonio Chiappa; Fabrizio Luca; Laura Zorzino; Paolo Pietro Bianchi; Laura Adamoli; Maria T Sandri; Maria G Zampino Journal: Int J Colorectal Dis Date: 2014-07-10 Impact factor: 2.571
Authors: U Bork; N N Rahbari; S Schölch; C Reissfelder; C Kahlert; M W Büchler; J Weitz; M Koch Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Anders S Frandsen; Anna Fabisiewicz; Agnieszka Jagiello-Gruszfeld; Anastasiya S Haugaard; Louise Munkhaus Petersen; Katrine Brandt Albrektsen; Sarah Nejlund; Julie Smith; Henrik Stender; Thore Hillig; György Sölétormos Journal: J Circ Biomark Date: 2015-06-30
Authors: Dominika Nesteruk; Andrzej Rutkowski; Stanisław Fabisiewicz; Jacek Pawlak; Janusz A Siedlecki; Anna Fabisiewicz Journal: Biomed Res Int Date: 2014-05-21 Impact factor: 3.411